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Context and Objective: Obesity in pregnancy is associated with increased risks of obesity in the
offspring.We investigated the relationshipbetweenobesity inpregnancyandcirculatingmaternal
and fetal levels of adipose tissue-derived factors adipsin and acylation stimulating protein (ASP) in
lean and obese mothers.
Design: Paired peripheral and cord blood samples were taken. Paired fat and placenta tissue were
taken for explant culture. Media were assayed for secreted adipsin and ASP. Clinical parameters
assayed included fasting insulin, glucose, and adipsin.
Setting: The study was conducted at a university hospital maternity unit.
Patients: Patients included 35 lean [bodymass index (BMI) 19–25 kg/m2, mean age 32 years and 39
obese (BMI) 30 kg/m2,mean age 32.49 years] pregnant Caucasianwomen, delivered by cesarean
section at term.
Main Outcome Measure: Identification of placental macrophages [Hofbauer cells (HBCs)], as a
source of adipsin and ASP was determined.
Results: HBCs secreted both adipsin and ASP. Cord levels of adipsin (1663.78  52.76 pg/mL) and
ASP (354.4817.17ng/mL)were significantlyelevated in theoffspringofobesemothers compared
with their lean controls [1354.66 33.87 pg/mL and 302.63 14.98 ng/mL, respectively (P .05 for
both)]. Placentae from obese mothers released significantly more adipsin and ASP than placentae
from lean mothers [546.0 44 pg/mL  g vs 284.56 43 pg/mL  g and 5485.75 163.32 ng/mL  g
vs 2399.16  181.83 ng/mL  g, respectively (P  .05 for both)]. Circulating fetal adipsin and ASP
positively correlated with maternal BMI (r 0.611, P .0001, and r 0.391, P .05, respectively).
Fetal adipsin correlated positively with maternal (r 0.482, P .01) and fetal homeostasis model
assessment of insulin resistance (r  0.465, P  .01).
Conclusions: We demonstrate novel secretion of adipsin and ASP by placental HBCs. (J Clin
Endocrinol Metab 98: 4113–4122, 2013)
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The prevalence of obesity is increasing and now affectsmore than 475 million individuals worldwide (1).
The fact that obesity may be transmissible via nongenetic
factors raises significant concerns for future generations.
Obesity is proving a major clinical problem in women of
reproductive age. It is currently estimated that one in four
pregnant patients in the United Kingdom are classified as
obese (2). Numerous studies have demonstrated that ma-
ternal obesity is related not only to increased risks for the
mother but also the offspring (3). In addition to being
associated with infertility, stillbirth, gestational diabetes
and hypertension, preeclampsia and complication during
delivery, maternal high body mass index (BMI) (30 kg/
m2) is positively correlated with neonatal and childhood
obesity in the offspring (4), with negative consequences
that include increased risk of metabolic syndrome (5) and
type 2 diabetes later in life (6).
Although it is established that increased maternal adi-
posity directly affects the physiology of the fetus, the
mechanisms by which these processes occur are incom-
pletely understood (7, 8). More recently, animal studies
have revealed mechanistic involvement of adipose tissue
derived factors in maternal obesity as well as a crucial
influence onmetabolic pathways and programming in the
fetus (9). However, comparatively limited work has been
performed inhumans examining the role of adipose tissue-
derived factors in obese pregnancy.
Adipsin was originally identified as a 28-kDa adi-
pocyte-secreted protease with close homology to human
complement D. Adipsin was first described as an adipo-
kine (10) before being also detected in muscle (11), lung,
peripheral nerves (12), and, more recently, murine pla-
centa (13). Adipsin is secreted in significant amounts from
adipose tissue (12), and plasma adipsin levels are signifi-
cantly higher in obesity and positively related to BMI (14).
Adipsin is the rate-limiting enzyme in the formation of
acylation stimulating protein (ASP) (15), a factor contrib-
uting to lipid storage in the adipose tissue (16–18). Ad-
ipsin catalyzes the breakdown of complement factor C3
into C3a (17), which is then converted into ASP. ASP is a
76-amino acid protein that enhances triacylglycerol clear-
ance, resulting in reduced circulating triglyceride levels in
the animal (19).MolecularmechanismsunderliningASP’s
metabolic function have been identified. ASP regulates
lipid storage in the adipose tissue by increasing diacylglyc-
erol O-acyltransferase 2 activity (20), enhancing glucose
transport in adipocytes (17) and reducing hormone-sen-
sitive lipase activity (21). Therefore, the combined in-
creased in lipogenesis and decreased triglyceride break-
down results in ASP-driven enhancement of lipid
accumulation in the adipose tissue and concomitantly a
reduction of plasma triglyceride concentrations.
Moreover, ASP-induced triglyceride synthesis is not
only more potent than that triggered by insulin but also
appears to be independent but synergistic with insulin ac-
tion (22). Plasma adipsin and ASP levels are increased in
states of insulin resistance, and obese individuals display
significantly increased ASP levels (23), potentially con-
tributing to enhanced triglyceride storage in conditions of
impaired insulin function (24). Interestingly, insulin resis-
tance is a normal state developing inmothers during preg-
nancyand is associatedwith increasedASPconcentrations
in late gestation (25).
Despite the evidence that the adipsin-ASP pathway
could contribute to increasing fetal fat mass (26), neither
adipsin and ASP function nor the correlation between
their levels in mothers and the developing fetus has been
investigated in the context of obese pregnancy.
With this in mind, we undertook the following: 1) a sys-
temic investigation of adipsin and ASP levels in obese and
leangestational age-matchedwomenalongwith the analysis
of adipsin andASP levels in their corresponding cord blood,
and 2) we examined paired adipose tissue and placental ex-
plants to identify a potential source of these molecules.
Materials and Methods
Subjects
All study participants were pregnant women scheduled for
elective cesarean section delivering at 39–40weeks of gestation.
Thirty-five lean (BMI19–25kg/m2,mean age 32 y; range 18–44
y) and 39 obese (BMI  30 kg/m2, mean age 32.49 y; range
22–44 y) Caucasian women were asked to fast overnight prior
to undergoing elective cesarean section, whichwas performed at
the same timeof the day in all individuals tomitigate anypossible
diurnal influences on adipsin andASP levels. The Coventry local
research ethics committee approved the study, and all patients
gave written informed consent (Research Ethics Committees 07/
H1210/141). We defined the control group as lean pregnant
women with prepregnancy BMI between 19 and 25 kg/m2 and
the test group as obese pregnant women with pregravid BMI
greater than 30.0 kg/m2. Oral glucose tolerance tests were per-
formed at 26–28 weeks of gestation in all participants to char-
acterize glucose metabolism and exclude diabetes. Women with
multiple pregnancies as well as patients with cardiovascular dis-
ease, preeclampsia, or other relevant diseases were excluded.
Paired maternal venous and cord blood samples were collected
at the time of cesarean section and were spun (3000  g; Beck-
man Coulter DS-9623C) immediately. The supernatant was
stored immediately at 80°C until analysis. All chemicals and
reagents were from Sigma-Aldrich unless otherwise stated.
Biochemical and hormone analysis
Venous blood samples were collected for themeasurement of
insulin, glucose, adipsin, ASP, nonesterified fatty acids (NEFAs),
and leptin and for lipid profiling. Details are provided in Sup-
plementalMethods, published on The Endocrine Society’s Jour-
nals Online web site at http://jcem.endojournals.org.
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Tissue explant culture
Paired explant experiments were performed using sc adipose
tissue and placentae (27, 28) from obese and lean pregnant pa-
tients undergoing elective cesarean section at term (n  4 for
both). Details are provided in in supplemental Methods.
Immunohistochemistry
Eight-micrometer frozenplacental andadipose tissue sections
were obtained using a cryostat (LeicaMicrosystems) and fixed in
75% ethanol for 5 minutes. Immunohistochemistry analyses
were performed on serial sections of placenta and adipose tissue
as described previously (29). Immunostaining was performed
using a Vector Polymer detection kit (Vector Laboratories), and
adipsin positive cells were detected with mouse antihuman
adipsin antibody (1:100; Santa Cruz Biotechnology). Assess-
ment of Hofbauer cell (HBC) numbers was performed by
staining with the Hofbauer Cell marker CD206 (R & D Sys-
tems), whereas the assessment of adipose tissue macrophages
was performed with the pan-macrophage marker CD68
(Dako). Cell counting was performed using ImageJ software
(National Institutes of Health) (30).
Western blotting
Proteinswereharvestedinradioimmunoprecipitationassaybuf-
fer with protease inhibitor cocktail added at 0.1% (vol/vol) (Cell
Signaling). Further details are provided in Supplemental Methods.
Isolation of placental cytotrophoblast, fibroblast,
and Hofbauer cells
Placental cells were isolated as previously described (31).
Briefly, isolation of the different cell types comprising placenta
was initiated through protocols previously used to obtain cy-
totrophoblasts (CTs) using trypsin/ deoxyribonuclease I diges-
tion and discontinuous Percoll gradient fractionation. CTs
(95% purity) were generated after enzymatic digestion of pla-
centa with trypsin, centrifugation on Percoll gradients, and neg-
ative immunoselection by simultaneous incubation with anti-
CD45 and anti-CD9 antibodies. HBCs were isolated using
collagenase digestion of trypsin-treated tissues, followed by cen-
trifugation on Percoll gradients and negative immunoselection
by sequential incubation with antiepithelial growth factor re-
ceptor and then with anti-CD10 antibodies. Cultures of fibro-
blasts (FIBs) (95%purity)were obtained fromcells attached to
magnetic beads containing CD9 and CD45 antibodies from CT
isolations and those attached to anti-CD10 beads from HBC
preparations. HBCs are isolated with 98%–99% purity and a
yield of 130–200 106 cells per 80–100 g of tissue assessed by
flow cytometry as previously described (31).
Confocal microscopy
Placental sections were obtained as described in Immunohis-
tochemistry.Details of confocalmicroscopy are provided in Sup-
plemental Methods.
Statistical analyses
Data are expressed asmean SEM.Differences between two
groups were compared using the Mann-Whitney U test, with
significance set at a P  .05. Correlations between parameters
were examined by bivariate analyses, using Pearson coefficients.
Multiple linear regression analysis was performed using SPSS
(IBM, version 19). Insulin resistance was estimated using the
homeostasis model assessment of insulin resistance (HOMA-
IR), calculated as [fasting insulin (microinternational units per
milliliter)  fasting glucose (millimoles per liter)/22.5] (32).
Results
Patient characteristics and biochemical profiles
Patient clinical characteristics are presented in Table 1,
whereas the maternal and fetal biochemical profiles are
summarized in Table 2. There were no significant differ-
ences in glucose and high-density lipoprotein cholesterol
levels between normal and obesewomenor their offspring
(P  .05). However, statistically significant differences
(P< .05)were found in total cholesterol, triglycerides, and
low-density lipoprotein, which were all elevated in obese
mothers as well as their corresponding fetal cord bloods
when compared with the group with normal BMI. Simi-
larly, serum insulin levels were significantly (P  .008)
elevated in obese women compared with lean women. In-
sulin concentrations were not statistically different in the
cord bloods of babies born to obese women compared
with lean women. HOMA-IR was elevated in obese
women (2.44 0.21) and their offspring, as measured via
cord blood (2.17  0.29), compared with lean women
(1.84  0.28) and their babies (1.37  0.08).
Table 1. Clinical Characteristics of Control and Obese Patients
Characteristics Control (n  35) Obese (n  39) P Value
Maternal age, y 32 (18–44) 32.487 (22–47) NS
Booking BMI, kg/m2 23.477 (20–24.9) 33.723 (30–46) .01
Gestational weight gain, kg 12.6  4.8 11.1  5.6 NS
Gestational age at delivery, wk 39  2 39  2 NS
OGTT 2 hours, mmol/L 5.44  0.31 5.60  0.25 NS
Birth weight, kg 3.51  0.04 3.61  0.03 .05
HOMA-IR mother 1.84  0.283 2.436  0.21 .001
HOMA-IR baby 1.365  0.08 2.171  0.288 .001
Abbreviations: NS, not significant; OGTT, oral glucose tolerance test.
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Elevated plasma adipsin in obese pregnancy
Plasma adipsin levels (Figure 1A) were significantly el-
evated in obese pregnant women (843.42 33.14 pg/mL)
compared with pregnant women with normal BMI
(720.63  33.13 pg/mL). Cord blood samples revealed
significantly higher levels of adipsin than maternal sam-
ples. Furthermore, babies born to obese mothers showed
significantly higher levels of adipsin (1663.78  52.76
pg/mL) in the cordbloods, as comparedwithbabiesof lean
mothers (1354.37  33.82 pg/mL) (P  .05).
Elevated plasma ASP in obese pregnancy
Plasma ASP levels (Figure 1B) were significantly ele-
vated in obese pregnant women (608.70 67.15 ng/mL),
compared with pregnant women with normal BMI
(420.30  39.98 ng/mL). In contrast to the observed in-
creased levels of adipsin, cord blood sample levels for ASP
were lower than maternal samples, but offspring of obese
mothers had significantly (P  .05) higher levels of cord
blood ASP (354.48 12.12 ng/mL) than the offspring of
lean mothers (302.63  14.98 ng/mL).
Secretion of adipsin and ASP by paired human
placental and adipose tissue explants
We identified adipsin secretion from placental ex-
plants, which was significantly greater in placentae from
obese patients (446.0  44.38 pg/mL  g) than from pla-
centae from lean patients (384.56 43 pg/mL  g;P .05)
(Figure 1C). Additionally and as expected, adipose tissue
(AT) from obese patients produced significantly more ad-
ipsin (790.27 64.60 pg/mL  g) thanAT from leanmoth-
ers (504.74 31.94 pg/mL  g; P .05). To test whether
human placenta was also producing ASP, similar analyses
on placental explant media were performed and revealed
that ASP secretion (Figure 1D)wasmarkedly greater from
placental tissues than from AT. ASP levels in the medium
of placental tissues of obese women (5485.74  163.32
ng/mL  g) were significantly higher than those of lean
women (2399.16181.83ng/mL  g). Similarly, although
to a lesser extent, ASP secretion from adipose tissue of
obese women (1508.40  659.65 ng/mL  g) was signifi-
cantly higher than ASP secretion from adipose tissue of
lean women (807.21  254.8 ng/mL  g).
Cord and maternal nonesterified fatty acid (NEFA)
levels
Given the elevated levels of adipsin and ASP in our
obese patient cohort, we examined circulating levels of
NEFAs in the fetal andmaternal compartments.Measure-
ment of NEFAs showed that obese mothers had higher
circulating NEFAs than their lean counterparts (1.35 
0.06 mol/L vs 1.09 0.18 mol/L) (Figure 1E). The
fetal compartment showed a similar pattern (0.19 0.02
mol/L vs 0.12  0.011 mol/L), with a 10-fold re-
duction in NEFA levels compared with the maternal cir-
culation, which is consistent with previous findings (33).
This was noted to be a similar order of magnitude to the
reduction in triglyceride concentrations (Table 2) between
the maternal and fetal compartments.
Fetal plasma adipsin and ASP correlations
APearson product-moment correlation coefficient was
computed to assess the relationship between fetal adipsin
and other clinical and biochemical parameters. Figure 2A
reveals a significant relationship between fetal adipsin and
maternal BMI (r 0.611, P .01). Correlations between
adipsin and other parameters are presented in Figure 2C.
The predictors of fetal adipsin levels were assessed by a
multiple regression analysis. Themodel includedmaternal
BMI, HOMA-IR, and leptin as independent variables.
Maternal BMI explained 37.7% (P  .006) of the varia-
tion in fetal adipsin.Maternal HOMA-IR accounted for a
further 8% (P  .036) of the variation in fetal adipsin.
There was a significant correlation between fetal ASP
and maternal BMI (r  0.391, P  .05) (Figure 2B). The
remaining correlations between ASP and other clinical/
Table 2. Biochemical Profiles of Maternal and Cord Blood From Control and Obese Patients
Biochemical Parameters
Maternal Cord
Normal BMI
(n  35)
High BMI
(n  39) P Value
Normal BMI
(n  35)
High BMI
(n  39) P Value
Glucose, mmol/L 4.288  0.055 4.279  0.098 .938 3.732  0.067 3.869  0.072 .168
Triglycerides, mmol/L 2.494  0.12 2.887  0.14 .037a 0.209  0.013 0.269  0.02 .014a
Total cholesterol, mmol/L 6.086  0.235 6.743  0.194 .036a 1.562  0.059 1.734  0.059 .043a
HDL cholesterol, mmol/L 1.744  0.069 1.671  0.07 .459 0.813  0.042 0.732  0.039 .163
LDL cholesterol, mmol/L 3.488  0.175 4.011  0.152 .029a 0.722  0.028 0.879  0.044 .003a
Insulin, IU/mL 11.871  1.267 17.815  1.782 .008a 8.976  0.763 11.4  2.099 .283
Leptin, ng/mL 23.933  2.66 48.603  2.801 .001a 2.674  0.2 4.862  0.54 .05
Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; n, number of cases. Data are mean  SEM.
a Statistically significant.
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biochemical parameters are presented in Figure 2C. We
also additionally observed that maternal adipsin levels
correlatedwithmaternal triglycerides (r0.329,P .04)
and fetal cholesterol (r  0.280, P  .038), whereas ma-
ternalASPcorrelatedwithbothmaternal triglycerides (r
0.492, P  .004) as well as maternal cholesterol (r 
0.370, P  .04). Furthermore, fetal adipsin correlated
with fetal triglycerides (r  0.287, P  .01).
Thepredictorsof fetalASP levelswerealso estimatedby
multiple regression analysis. Themodel includedmaternal
BMI,HOMA-IR, and leptin as independent variables.The
model explained that only maternal BMI accounted for
26% of the variation in fetal ASP (P  .016).
Human placenta secretes adipsin
Immunohistochemistry experiments revealed adipsin
positive areas in specific cells dispersed throughout the pla-
centa (Figure 3A). Pronounced stainingwas particularly ob-
served in the perivascular area, suggesting higher levels of
adipsin in proximity to the fetal vasculature (Figure 3B). The
distribution of these cells suggested that they were HBCs.
Antibody specificity was confirmed by immunoblotting,
with human adipose tissue as positive control (Figure 3C).
Confocal microscopy revealed that adipsin colocalized
with CD206, a HBCmarker (Figure 3D, upper panels), but
adipsin did not colocalize with the trophoblast marker CK7
(Figure 3D, lower panels), therefore demonstrating that ad-
ipsin colocalized to the placental macrophages (HBCs).
HBCs secrete both adipsin and ASP
The previous observations strongly suggested that HBCs
in the placenta produced adipsin and ASP. Therefore, to ad-
dress thispossibilityandtoexcludeacontributionfromother
cell types within the placenta, negativemagnetic selection of
Figure 1. Measurements of adipsin, ASP, and NEFA concentrations. A, Adipsin concentration in maternal and cord plasma. B, ASP concentration
in maternal and cord plasma. C, Measurement of secreted adipsin from paired placental (n  5) and adipose tissue explants (n  5) between
normal and obese patients. D, Measurement of secreted ASP from paired placental (n  5) and adipose tissues explants (n  5) between normal
and obese patients. E, NEFA concentration in maternal and cord plasma. Cont, control. *, P  .05
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cell types from placenta was performed as previously de-
scribed (31). FIBs, cytotrophoblasts (CTBs), andHBCs from
4 placentae were cultured and adipsin and ASP were quan-
tified in their respective media. Although only minimal ASP
or adipsin was found in either FIBs or CTBs, sustained se-
cretion of both adipsin (49.75 pg/ml per 106 cells) and ASP
(13.62ng/mLper 106 cells)was detected fromHBCs (Figure
4, A and B, respectively).
Quantification of macrophages and HBCs in obese
vs normal placental and adipose tissue
ImageJ analysis of macrophage marker staining in ad-
ipose tissue (Figure 4, F and G) revealed increased mac-
rophage numbers in obese adipose comparedwith normal
[14.70  0.92 vs 10.85  0.78 (Figure 4H), P  .05] as
well as significantly higherHBC counts in obese placentae
(Figure 4, C and D) compared with normal placentae
[22.05  1.23 vs 18.09  1.08, respectively (Figure 4E),
P .05] respectively, both results confirming the previous
finding (34, 35).
Discussion
Adipsin and ASP play significant roles in triglyceride stor-
age, and their levels rise both after high-fat meals and in
Figure 2. A, Relationship between fetal adipsin concentrations and maternal body mass index. B, Relationship between fetal ASP concentrations
and maternal body mass index. C, Pearson correlation coefficients between fetal adipsin and fetal ASP with other covariates. P values are in
brackets. NS, not significant; TG, triglycerides.
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obese states (36). Pregnancy is characterized by an insulin-
resistant state with significant metabolic perturbations,
which are exaggerated by maternal obesity. Although the
adipsin/ASP pathway has been investigated in obesity (23)
and plays a significant role in lipogenesis (37), limited
information is available on the role of adipsin in preg-
nancy. ASP levels correlate with maternal hyperlipidemia
in late gestation (25). Although our findings corroborate
these observations, examining the role of ASP in hyper-
lipidemia in state of obesity was beyond the scope of this
study. Instead, we report for the first time that circulating
adipsin levels are increased in obese mothers compared
with their lean controls. Most importantly, adipsin levels
were significantly higher in the cord bloods than in the
maternal circulation, with an even greater elevation in the
cord bloods fromobesemothers. In conjunctionwith this,
elevated circulating ASP levels were noted in the obese
group. Although ASP levels in the cord bloods were lower
than those seen in the mothers, there were significantly
higher levels in the cord bloods from obese mothers than
cord bloods from lean mothers.
There were strong correlations between both fetal ad-
ipsin and fetal ASP with maternal BMI, suggesting poten-
tially important roles for this pathway in pregnancy as
well as correlations between maternal and fetal adipsin
andASPwithmaternal triglycerides, cholesterol, and fetal
triglycerides and cholesterol.We found, in agreementwith
other studies (38), that our obese group did not gain more
weight than our lean cohort. According to Institute of
Medicine and Health Canada’s gestational weight gain
recommendations (39), a more moderate weight gain in
obese mothers of 5–9 kg of gestational weight gain would
be preferable, with the here observed mean weight gain of
11.1 kg being slightly higher. However, because absolute
weight gain was comparable between lean and obese
mothers, increased levels of adipsin and ASP in the obese
mothers and their fetuses cannot be attributed to a higher
increase of maternal weight in obese mothers in this co-
hort. We did note significant correlations between fetal
adipsin and fetal birth weight, suggesting a possible con-
tribution to fetal programming of obesity. Nevertheless,
whether high adipsin and/or ASP levels in the fetusmay be
causally involved in increased birth weight remains to be
investigated.
Given these data, the significantly elevated levels of ad-
ipsin observed in the cord blood suggest that the placenta
Figure 3. Immunohistochemistry, immunofluorescence, and Western blotting. A, Immunohistochemical detection of adipsin in placental tissues;
image was taken at 10. B, Perivascular localization image taken at 20. C, Western blotting of adipsin and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in adipose (Ad.Tissue) and placental tissues. D, Immunofluorescence images of adipsin and CD206 revealing
colocalization (upper panels) and adipsin and CK7 revealing no colocalization (lower panels).
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might be a source of these molecules. We therefore under-
took paired explant experiments using sc adipose tissue,
which releases similar amounts of adipsin than visceral
tissue (40), and placenta. We demonstrate that placental
explants secreted both adipsin and ASP into the media.
Adipsin secretion from placental explants was lower than
that seen from the paired adipose tissue explants. How-
ever, ASP secretion had a strikingly opposite pattern, ie,
ASP from placental explants was substantially greater
than that seen from adipose tissue. Moreover, although
the secretion of adipsin from the placental explants was
translated into high levels of adipsin in cord blood, higher
levels of ASP released by placental explants did not par-
allel levels of cord ASP. Given the normal levels of adipsin
secretion from the explants, the elevated ASP seen in pla-
cental explants lends itself to the hypothesis that the pla-
centa might use ASP locally.
Consistent with previous findings (33) was the obser-
vation that circulating triglyceride and NEFA levels were
significantly lower in the fetal compartment. This is not
unexpected when analyzing whole cord blood samples,
given that whole cord blood represents both blood into
fetal circulation via the umbilical vein and blood back to
the placenta via the umbilical artery. Thus, returning
blood would have reduced NEFAs because the fetus uses
fatty acids. However, an additional physiological action
of ASP at the placental barrier cannot be finally excluded.
The finding that triglyceride and NEFA levels were lower
in the fetal compartment does not obviate the finding that
the offspring of obese mothers had higher levels of these
lipid species than those of their lean counterparts. In
healthy men and nonpregnant women, fasting ASP pre-
dicts postprandial triglyceride clearance (41). Moreover,
fasting plasma ASP is increased in obesity, insulin resis-
tance, coronary artery disease, and diabetes (42), whereas
weight loss and exercise decreaseASP (43). It has therefore
been suggested that increased levels of fasting ASP, in the
presence of delayed triglyceride clearance, are suggestive
ofASP resistance (44).Our datamay indicate an enhanced
adipsin/ASP response in obesity, which is insufficient to
Figure 4. Measurement of adipsin (A) and ASP (B) secretions from isolated CTBs, FIBs, and HBCs. Significant secretion of adipsin and ASP was
noted from HBCs. *, P  .001. HBC staining with CD206 in normal (C) and obese (D) placentae reveals increased numbers after counting using
ImageJ (E). Macrophage staining with CD68 in normal (F) and obese (G) paired adipose tissue reveals increased numbers (H) after counting. Cont,
control.
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completely mitigate the elevated lipids in the fetus. Our
data would support the hypothesis of ASP resistance in
obese pregnancy, but further studies are needed to eluci-
date this.
Having demonstrated novel placental secretion of both
adipsin and ASP, we aimed to identify the cell type(s)
within the placenta that was responsible for the synthesis
and/or secretion of these molecules. It has previously been
demonstrated in adipose tissue that the stromal vascular
compartment is responsible for the release of adipsin (40).
The placenta is a complex organ, comprised of tropho-
blasts (cytotrophoblast and syncytiotrophoblast), endo-
thelial cells, connective tissue, fibroblasts, and HBCs that
are macrophages of mesenchymal origin and are present
throughout pregnancy. Immunohistochemistry revealed
perivascular staining of adipsin in a cell type that was
neither endothelial nor trophoblast. Because positive
staining was localized to areas with both fibroblasts and
HBCs, we further aimed to identify the responsible cell
type using confocalmicroscopy and a negative immunose-
lection technique that we have previously used to isolate
cell types from the placenta (31). Confocal microscopy
showedHBCsandadipsin colocalization. In addition, cul-
turing separated cytotrophoblasts; fibroblasts, and HBCs
revealed that both adipsin and ASP were released from
HBCs, with negligible release from any of the other cell
types seen. We also detected increased numbers of mac-
rophages andHBCs in adipose tissues and placentae from
obese mothers, as previously reported (34, 35), and these
increased macrophage/HBC numbers might explain the
circulating levels of these hormones.
This novel finding indicates that HBCs release mole-
cules associated with the regulation of triglyceride metab-
olism. The presence of the adipogenic adipsin/ASP path-
way in theHBCs of the placenta togetherwith the elevated
levels of adipsin in the fetal circulation andour correlation
data suggest potential roles in regulation of triglyceride
metabolism in the fetus.
Strengths of our study include the relatively large num-
ber of subjects investigated and the use of ex vivo explants,
which supported our findings. Limitations include the
use of estimates of insulin sensitivity rather than mea-
suring this parameter using euglycemic hyperinsuline-
mic clamps and the lack of information about body fat
distribution in the pregnant participants (although lep-
tin was used as a surrogate marker). Finally, despite the
clear evidence of placental secretion of adipsin and ASP
via HBCs, the possibility that maternal adipsin/ASP
might contribute to the fetal levels, perhaps by crossing
the placental barrier, cannot completely be excluded,
and further work beyond the scope of this manuscript is
required to elucidate this.
In conclusion, we hypothesize that given the relative
insulin resistance in pregnancy, and particularly in obese
pregnancy, that adipsin and ASP might play a role in tri-
glyceride metabolism in pregnancy. Our data place HBCs
as a source of these metabolically active molecules.
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